Published in BMJ on February 15, 2003
Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res (2010) 2.21
Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator. BMJ (2009) 1.37
The Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the future. BMC Neurol (2009) 1.12
Access to high cost drugs in Australia. BMJ (2004) 1.07
Escalating immunotherapy of multiple sclerosis--new aspects and practical application. J Neurol (2004) 0.88
Addressing uncertainties about the effects of treatments offered to NHS patients: whose responsibility? J R Soc Med (2007) 0.87
Valorising and creating access to innovative medicines in the European union. Front Pharmacol (2011) 0.81
Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis. J Neurol (2007) 0.81
Let cost effectiveness models be open to scrutiny. BMJ (2007) 0.81
Diagnosis and disease modifying treatments in multiple sclerosis. Postgrad Med J (2005) 0.77
Shared scheme for assessing drugs for multiple sclerosis: cost effective provision of effective treatments for multiple sclerosis. BMJ (2003) 0.76
Shared scheme for assessing drugs for multiple sclerosis: why are eyes tightly shut to considering causes other than autoimmunity? BMJ (2003) 0.75
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology (1983) 40.64
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol (1996) 10.39
Randomized versus historical controls for clinical trials. Am J Med (1982) 7.53
The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials. BMJ (1998) 5.05
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet (2001) 4.55
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med (2000) 4.50
Interferons in the treatment of multiple sclerosis: do they prevent the progression of the disease? Arch Neurol (1998) 3.55
The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology (1994) 2.95
Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med (1985) 2.59
A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med (1987) 2.21
The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain (1991) 2.11
Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results. Neurology (2001) 1.95
Interferon in relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev (2001) 1.88
Overview of azathioprine treatment in multiple sclerosis. Lancet (1991) 1.83
The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain (1999) 1.30
A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology (1991) 1.29
Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology (1997) 1.14
Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group. Neurology (1999) 1.13
Double-blind controlled trial of immunosuppression in the treatment of multiple sclerosis: final report. Lancet (1982) 1.09
Long-term treatment of multiple sclerosis with azathioprine. J Neurol Neurosurg Psychiatry (1973) 1.09
Disease-modifying drugs for multiple sclerosis: a rapid and systematic review. Health Technol Assess (2000) 1.08
Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology (1996) 1.03
Double-masked trial of azathioprine in multiple sclerosis. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Lancet (1988) 1.01
The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology (1991) 0.94
A double blind study on azathioprine efficacy in multiple sclerosis: final report. J Neurol (1993) 0.91
A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis. Neurology (1989) 0.89
Outcome after interventional or conservative management of unruptured brain arteriovenous malformations: a prospective, population-based cohort study. Lancet Neurol (2008) 2.39
Untreated clinical course of cerebral cavernous malformations: a prospective, population-based cohort study. Lancet Neurol (2012) 1.79
Seizure risk with AVM treatment or conservative management: prospective, population-based study. Neurology (2012) 1.56
Mortality in Parkinson's disease: a systematic review and meta-analysis. Mov Disord (2014) 1.04
The presentation and clinical course of intracranial developmental venous anomalies in adults: a systematic review and prospective, population-based study. Stroke (2009) 0.96
Predicting functional outcome after stroke by modelling baseline clinical and CT variables. Age Ageing (2010) 0.94
Pilot study of the incidence and prognosis of degenerative Parkinsonian disorders in Aberdeen, United Kingdom: methods and preliminary results. Mov Disord (2006) 0.94
The impact of motor and non motor symptoms on health state values in newly diagnosed idiopathic Parkinson's disease. J Neurol (2011) 0.93
Patterns of brain arteriovenous malformation treatment: prospective, population-based study. Stroke (2008) 0.89
A new prevalence study of multiple sclerosis in Orkney, Shetland and Aberdeen city. J Neurol Neurosurg Psychiatry (2012) 0.86
Timed tests of motor function in Parkinson's disease. Parkinsonism Relat Disord (2010) 0.85
A systematic review of biomarkers for disease progression in Parkinson's disease. BMC Neurol (2013) 0.84
Shape analysis of 123I-N-omega-fluoropropyl-2-beta-carbomethoxy-3beta-(4-iodophenyl) nortropane single-photon emission computed tomography images in the assessment of patients with parkinsonian syndromes. Nucl Med Commun (2009) 0.81
Non-completion of changes to prescribed medications in people with Parkinson's disease. Age Ageing (2007) 0.81
Developing a sensitive search strategy in MEDLINE to retrieve studies on assessment of the diagnostic performance of imaging techniques. Radiology (2008) 0.78
In a randomized study of envelope and ink color, colored ink was found to increase the response rate to a postal questionnaire. J Clin Epidemiol (2006) 0.77
Comparison of patient rated treatment response with measured improvement in Parkinson's disease. J Neurol Neurosurg Psychiatry (2012) 0.77
Parkinson's disease misdiagnosed as stroke. BMJ Case Rep (2009) 0.77
The use of decision-analytic models in Parkinson's disease: a systematic review and critical appraisal. Appl Health Econ Health Policy (2011) 0.76
Orphan drugs. Regulation is flawed. BMJ (2010) 0.75
Maximizing patient consent for video recording. Mov Disord (2004) 0.75